Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amplifon SpAAMFPF 78 Equity-to-Asset is 0.27 as of Mar. 2026, which is 7% below its 10-year median of 0.29. GuruFocus rates AMFPF with a GF Score™ of 78/100 and a GF Value™ of $27.92 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 118 Medical Distribution companies, Amplifon SpA ranks worse than 71.19% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Amplifon SpA's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $1,244 Mil. Amplifon SpA's Total Assets for the quarter that ended in Mar. 2026 was $4,541 Mil.
Therefore, Amplifon SpA's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.27.
The historical rank and industry rank for Amplifon SpA's Equity-to-Asset or its related term are showing as below:
AMFPF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.22 Med: 0.29 Max: 0.4
Current: 0.27
During the past 13 years, the highest Equity to Asset Ratio of Amplifon SpA was 0.40. The lowest was 0.22. And the median was 0.29.
AMFPF's Equity-to-Asset is ranked worse than 71.19% of 118
companies
in the Medical Distribution industry
Industry Median: 0.39
vs AMFPF: 0.27
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Amplifon SpA Equity-to-Asset Related Terms
Amplifon SpA Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Amplifon SpA's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMFPF vs MCK, CAH, COR: Equity-to-Asset Comparison
For the Medical Distribution subindustry, Amplifon SpA's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amplifon SpA Equity-to-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Amplifon SpA's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Amplifon SpA's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Amplifon SpA's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amplifon SpA (AMFPF) has a Equity-to-Asset of 0.27 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Amplifon SpA and its competitors. This is near median its historical median of 0.29. Over the past decade, Amplifon SpA's Equity-to-Asset has ranged from 0.22 to 0.40. According to the industry distribution chart, Amplifon SpA ranks #84 out of 118 companies in the Medical Distribution industry, placing it in the top 71.2%.
Is Amplifon SpA's Equity-to-Asset too high?
Amplifon SpA's current Equity-to-Asset of 0.27 is near median its 10-year median of 0.29. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 0.40. The Medical Distribution industry median Equity-to-Asset is 0.39. Amplifon SpA's value of 0.27 is 30.8% below this industry median. Based on the distribution chart, Amplifon SpA ranks #84 out of 118 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Amplifon SpA has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Amplifon SpA's Equity-to-Asset compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Amplifon SpA ranks #84 out of 118 companies for Equity-to-Asset. This places Amplifon SpA in the lower half of its industry. The industry median Equity-to-Asset is 0.39. Amplifon SpA's value of 0.27 is 30.8% below this benchmark. Historically, Amplifon SpA's own Equity-to-Asset has ranged from 0.22 to 0.40 over the past decade. While the company's 10-year median is 0.29 vs. the industry median of 0.39, Amplifon SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Distribution company?
The median Equity-to-Asset among Medical Distribution companies is 0.39, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amplifon SpA's current Equity-to-Asset of 0.27 is 30.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Amplifon SpA and its competitors. For the Medical Distribution industry, the median Equity-to-Asset is 0.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amplifon SpA's current Equity-to-Asset is 0.27, which is near median its own 10-year median of 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplifon SpA stock overvalued right now?
Based on GuruFocus' analysis, Amplifon SpA (AMFPF) is currently considered Possible Value Trap. The stock's GF Value™ is $27.92, compared to a current price of $11.21 — trading 59.8% below its estimated fair value. The current Equity-to-Asset is 0.27, which is near median its 10-year median of 0.29 and 30.8% below the Medical Distribution industry median of 0.39. Amplifon SpA's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Amplifon SpA (AMFPF), the current Equity-to-Asset is 0.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amplifon SpA (AMFPF) Overvalued in 2026?
Based on GuruFocus' analysis, Amplifon SpA stock appears to be undervalued.
The current stock price of $11.21 is trading 59.8% below its estimated GF Value™ of $27.92.
GuruFocus considers Amplifon SpA to be Possible Value Trap.
Key valuation signals for AMFPF:
Equity-to-Asset: 0.27 (near median its 10-year median of 0.29)
GF Value™: $27.92 vs. price of $11.21 (59.8% below fair value)
Industry Position: 30.8% below the Medical Distribution median (#84 of 118)
No single metric tells the full story. See the AMFPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amplifon SpA provides customizable hearing solutions and services through a distribution network of network affiliates, corporate shops, franchises, and shop-in-shops. The company operates in three segments based on geography: the Americas; Europe, the Middle East, and Africa; and Asia-Pacific. It generates the majority of its revenue in the EMEA region. It operates under a variety of brands in these regions, including Amplifon, Beter Horen, Maxtone, and Miracle-Ear.
78GF Score
Get the complete analysis for AMFPF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMFPF has been successfully added to your 
